
Clinical Pharmacology During Pregnancy
- 2nd Edition - September 23, 2021
- Imprint: Academic Press
- Editors: Donald Mattison, Lee-Ann Halbert
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 8 9 0 2 - 3
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 8 9 0 3 - 0
Clinical Pharmacology During Pregnancy, Second Edition is written for clinicians, physicians, midwives, nurses, pharmacists and other medical professionals involved in the care… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteClinical Pharmacology During Pregnancy, Second Edition is written for clinicians, physicians, midwives, nurses, pharmacists and other medical professionals involved in the care of women during pregnancy. The book focuses on the impact of pregnancy on drug disposition and includes coverage of treatments for diseases of specific body systems as well as essential content on dosing and efficacy. This update includes substantially expanded sections on the ethics of pharmacological research in pregnancy and physiologic changes, along with new sections on patient reported outcomes in pregnancy, delivery and postnatal care, and the use of pharmacokinetic and pharmacodynamic approaches to estimate maternal, placental and fetal dosing.
The broad range of this book encompasses analgesics, antiasthmatics, antidepressants, heart and circulatory drugs, vitamins and herbal supplements, and more. Topics in chemotherapy and substance abuse are also covered, as are research issues, including clinical trial design and ethical considerations.
- Uses an evidence-based approach for therapeutics during pregnancy
- Presents a summary of specific medications by indication, including up-to-date information on dosing and efficacy in pregnancy for the given indication
- Includes significant new sections on physiologic changes and the ethics of pharmacological research in pregnancy
Anyone who is actively involved in the care of pregnant women, including obstetricians, residents in obstetrics, fellows in fetal maternal medicine, internists, general and family practitioners who provide care for women of reproductive age, pharmacists, midwives, nurse practitioners and physician assistants
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Acknowledgment
- Chapter 1. Introduction
- Chapter 2. Physiologic changes during pregnancy
- 2.1. Physiologic changes during pregnancy
- 2.2. Cardiovascular system
- 2.3. Respiratory system
- 2.4. Renal system
- 2.5. Gastrointestinal system
- 2.6. Hematologic and coagulation systems
- 2.7. Endocrine system
- 2.8. Summary
- Chapter 3. Impact of pregnancy on maternal pharmacokinetics of medications
- 3.1. Introduction
- 3.2. Effects of pregnancy on pharmacokinetic parameters
- 3.3. Summary
- Chapter 4. Medications and the breastfeeding mother
- 4.1. Medication use by the breastfeeding mother
- 4.2. Clinical pharmacology of drug transfer into breast milk
- 4.3. During delivery
- 4.4. General anesthesia
- 4.5. Epidural anesthesia
- 4.6. Galactogogues including dietary supplements (including herbs)
- 4.7. Immediate postpartum period
- 4.8. Pain
- 4.9. Methadone
- 4.10. Resumption of prepregnancy medications
- 4.11. Psycho- and neurotropic drugs
- 4.12. Drugs not to give to the nursing mother postpartum
- 4.13. Oral contraceptives
- 4.14. Summary
- 4.15. Where to find information
- Chapter 5. Fetal drug therapy
- 5.1. Introduction
- 5.2. Indications for fetal therapy
- 5.3. Strategies to achieve fetal drug therapy
- 5.4. Special considerations
- 5.5. Ethical considerations
- Chapter 6. Treating the placenta: an evolving therapeutic concept
- 6.1. Introduction
- 6.2. The placenta as the therapeutic target: the past
- 6.3. The placenta: therapeutic targets
- 6.4. The placenta as a therapeutic target today
- 6.5. The placenta as a therapeutic target in the future
- 6.6. Conclusions
- Chapter 7. Conducting randomized controlled pharmaceutical trials in the pregnant population: challenges and solutions
- 7.1. Introduction
- 7.2. Ethical considerations
- 7.3. Including pregnant women in pharmaceutical trials for nonobstetrical conditions
- 7.4. Improving the success of drug trials for obstetrical conditions
- 7.5. Summary
- Chapter 8. Pharmacogenomics in pregnancy
- 8.1. Pharmacogenomics
- 8.2. Genetics and polymorphisms
- 8.3. Genes that influence pharmacokinetic variability
- 8.4. The current state of pharmacogenetic testing
- 8.5. Potential therapeutic areas for pharmacogenomics in pregnancy
- 8.6. Study designs and approaches to pharmacogenetics trials
- Chapter 9. Anesthetic drugs
- 9.1. Introduction
- 9.2. General anesthesia
- 9.3. Inhalational anesthetics
- 9.4. Intravenous anesthetics
- 9.5. Neuromuscular blocking agents
- 9.6. Regional anesthesia
- 9.7. Summary
- Chapter 10. The management of asthma during pregnancy
- 10.1. Introduction
- 10.2. Effect of pregnancy on the course of asthma
- 10.3. Effect of asthma on pregnancy
- 10.4. Asthma management
- 10.5. Pharmacologic therapy
- 10.6. Conclusion
- Chapter 11. Nausea and vomiting of pregnancy
- 11.1. Nausea and vomiting of pregnancy
- 11.2. Prevalence
- 11.3. Etiologies and pathogenesis
- 11.4. Burden of the disease
- 11.5. Cultural implications
- 11.6. Risk factors
- 11.7. Quantification
- 11.8. Effects on fetus
- 11.9. Late complications related to NVP
- 11.10. Approaches to treatment
- 11.11. Lifestyle alterations
- 11.12. Complementary and alternative medicine
- 11.13. Pharmacologic therapies
- 11.14. Differential diagnoses
- 11.15. Conclusion
- Chapter 12. Clinical pharmacology of anti-infectives during pregnancy
- 12.1. Antibacterial therapy
- 12.2. Antifungal therapy
- 12.3. Malaria
- 12.4. Tuberculosis
- 12.5. HIV
- 12.6. Antivirals
- 12.7. Parasitic infections
- Chapter 13. Chemotherapy in pregnancy
- 13.1. Introduction
- 13.2. Overview of chemotherapeutic agents
- 13.3. Treatment of specific cancers
- 13.4. Pharmacokinetics in pregnancy
- Chapter 14. Substance abuse in pregnancy
- 14.1. Introduction
- 14.2. Substance use disorders defined
- 14.3. Addiction defined as a disease of the brain
- 14.4. The good news: the brain can recover
- 14.5. Addiction in women and pregnancy
- 14.6. Psychiatric comorbidity
- 14.7. Substances used in pregnancy
- 14.8. Screening and detection
- 14.9. The role of urine and meconium testing
- 14.10. Brief office screening strategies
- 14.11. Brief office interventions
- 14.12. Long-term care and maintenance
- 14.13. Conclusion
- Chapter 15. Diabetes in pregnancy
- 15.1. Introduction
- 15.2. Epidemiology
- 15.3. Classification
- 15.4. Gestational diabetes
- 15.5. Diabetes management in pregnancy
- 15.6. Conclusion
- Chapter 16. Cardiovascular medications in pregnancy
- 16.1. Introduction
- 16.2. Resources for guidance
- 16.3. Cardiovascular changes in pregnancy
- 16.4. Cardiovascular disease in pregnancy
- 16.5. Mechanism of action for hypertensive medications
- 16.6. Coronary artery disease and Spontaneous Coronary Artery Dissection
- 16.7. Coronary Microvascular Disease and angina
- 16.8. Medications for cardiomyopathy
- 16.9. Electrophysiological
- Chapter 17. Antidepressants in pregnancy
- 17.1. Introduction
- 17.2. Effects of untreated perinatal depression on women and children
- 17.3. Approach to treatment
- 17.4. Potential risks of selective serotonin reuptake inhibitor use during pregnancy
- 17.5. Potential risks of non-SSRI antidepressant use during pregnancy
- 17.6. Potential risks of older antidepressant use during pregnancy
- 17.7. Anxiety
- 17.8. Summary
- Chapter 18. Uterotonics and tocolytics
- 18.1. Introduction
- 18.2. Uterotonics
- 18.3. Tocolytics
- Chapter 19. Antenatal thyroid disease and pharmacotherapy in pregnancy
- 19.1. Thyroid function and physiology in pregnancy
- 19.2. Hyperthyroidism in pregnancy
- 19.3. Pharmacotherapy with thionamides in pregnancy
- 19.4. Hypothyroidism in pregnancy
- 19.5. Pharmacotherapy with levothyroxine in pregnancy
- 19.6. Summary
- Chapter 20. Management of dermatological conditions in pregnancy
- 20.1. Introduction
- 20.2. Acne
- 20.3. Psoriasis
- 20.4. Oral agents
- 20.5. Dermatoses
- 20.6. Bacterial infections
- 20.7. Viral infections
- 20.8. Fungal infections
- 20.9. Parasitic infections
- 20.10. Dermatological wounds
- Chapter 21. Herbs and alternative remedies
- 21.1. Herbal teas frequently used during pregnancy
- 21.2. Essential oils used as aromatherapy during pregnancy
- 21.3. Herbs used as capsules or dried extracts
- 21.4. Herbal topical preparations used in pregnancy
- 21.5. Nonherbal supplements used in pregnancy
- 21.6. Herbs used to induce labor
- 21.7. Acupuncture and acupressure therapy in pregnancy
- 21.8. Meditation and hypnosis in pregnancy
- Chapter 22. Envenomations and antivenom during pregnancy
- 22.1. General principles about envenomation
- 22.2. Snake bites
- 22.3. Spider bites
- 22.4. Jellyfish
- 22.5. Antivenom use during pregnancy
- 22.6. Conclusions
- Chapter 23. Gastrointestinal disorders
- 23.1. Gastroesophageal reflux disease
- 23.2. Peptic ulcer disease
- 23.3. Constipation
- 23.4. Diarrhea
- 23.5. Abdominal pain
- 23.6. Gastrointestinal infections
- 23.7. Inflammatory bowel disease
- Liver diseases in pregnancy
- Chapter 24. Challenges in predicting the pharmacokinetics of drugs in premature and mature newborns: example with piperacillin and tazobactam
- 24.1. Introduction
- 24.2. What is a PBPK model?
- 24.3. Neonates are not just “little adults”
- 24.4. PIP and TAZ PBPK model for preterm and term neonates [49–51]
- 24.5. Ability of the neonate PBPK model to predict plasma levels of PIP and TAZ
- 24.6. Conclusions
- Index
- Edition: 2
- Published: September 23, 2021
- Imprint: Academic Press
- No. of pages: 506
- Language: English
- Paperback ISBN: 9780128189023
- eBook ISBN: 9780128189030
DM
Donald Mattison
LH